PRCT - NASDAQ
PROCEPT BioRobotics Corporation
$26.33
-1.6%PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
At a Glance
Live SnapshotPROCEPT BioRobotics Corporation Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
PROCEPT BioRobotics Corporation Income Statement
PRCT • NASDAQ
| PROCEPT BioRobotics Corporation Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
308.1M | 224.5M | 136.2M | 75M | 34.5M | 7.7M | 6.2M | |
GROSS PROFIT | |||||||
(111.8M) | (87.4M) | (65.1M) | (37.9M) | (18.6M) | (9M) | (8.1M) | |
196.2M | 137.1M | 71M | 37.1M | 15.9M | -1.3M | -1.9M | |
OPERATING INCOME | |||||||
(300.1M) | (233.7M) | (180.2M) | (117.8M) | (70M) | (46.5M) | (41.7M) | |
(228.8M) | (171.4M) | (131.8M) | (88.8M) | (51M) | (30.3M) | (28.5M) | |
(71.3M) | (62.3M) | (48.4M) | (29M) | (19M) | (16.3M) | (13.1M) | |
-103.9M | -96.6M | -109.2M | -80.7M | -54.2M | -47.8M | -43.6M | |
PRE-TAX INCOME | |||||||
(3.6M) | (4.2M) | (4M) | (5.2M) | (5.8M) | (5.3M) | (724K) | |
8.6M | 6.7M | 3.6M | -2.7M | -5.7M | -5.1M | 425K | |
8.5M | 5.2M | 3.3M | -6.4M | -5.7M | -5.2M | 1.6M | |
-95.4M | -91.4M | -105.9M | -87.2M | -59.9M | -53M | -42M | |
NET INCOME | |||||||
(190K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-95.6M | -91.4M | -105.9M | -87.2M | -59.9M | -53M | -42M |
SEC Filings
PRCT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | April 30, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 29, 2026 | April 29, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 22, 2026 | June 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 06, 2026 | March 05, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 25, 2026 | February 25, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 05, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 04, 2025 | November 04, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 18, 2025 | September 15, 2025 | 2025 |
Related Guides
Continue your PRCT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.